Cabaletta Bio to Participate in Upcoming Investor Conferences
Cabaletta Bio (Nasdaq: CABA) will participate in Guggenheim’s healthcare investor conference on November 10, 2026, with investor meetings and a webcasted fireside chat.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cabaletta Bio (Nasdaq: CABA) will participate in Guggenheim’s healthcare investor conference on November 10, 2026, with investor meetings and a webcasted fireside chat. The Boston chat begins at 9:00 a.m. ET. The company will also hold investor meetings and a webcasted fireside chat at the Jefferies Global Healthcare Conference in London on November 18 at 5:00 p.m. GMT (12:00 p.m. ET). Webcasts will be available on its website, with replays available for 30 days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences:
- Guggenheim’s 3rd Annual Healthcare Innovation Conference: Meetings with investors and a webcasted fireside chat at 9:00 a.m. ET on Tuesday, November 10, 2026, in Boston, MA.
- 2026 Jefferies Global Healthcare Conference in London: Meetings with investors and a webcasted fireside chat at 5:00 p.m. GMT (12:00 p.m. ET) on Wednesday, November 18, 2026, in London, UK.
The webcasted fireside chats will be accessible on the News and Events section of the Company’s website at www.cabalettabio.com. Archived replays will be available for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. Cabaletta’s lead product candidate, rese-cel, is an investigational 4-1BB-containing fully human CD19-CAR T cell therapy being advanced across the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology, and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts
Investors: investors@cabalettabio.com
Media: media@cabalettabio.com
